A pioneering breast cancer treatment will not be routinely available on the NHS because its price is “too high”, a watchdog has ruled. The National Institute for Health and Care Excellence published final draft guidance saying Kadcyla – which can give women dying from an aggressive form of breast cancer extra months of life – was not set at an affordable price.
Are you up for a challenge?
